Novo Nordisk's Two-Front Battle: A Missed Clinical Goal and a Chinese Opening

Novo Nordisk's CagriSema misses superiority vs Lilly, stock dips; oral Wegovy China filing and strong oral franchise provide counterbalance.

The Danish pharmaceutical giant finds itself navigating a decidedly mixed week. While its pipeline suffered a visible setback in the obesity arena, a regulatory filing in Asia offers a counterweight of optimism. For investors, the question is whether the bearish clinical narrative or the bullish market-expansion story will ultimately steer the share price.

The most immediate pressure stems from the Phase 3 Redefine 4 trial, where the combination therapy CagriSema delivered a 23.0 percent weight loss. That figure, while substantial, fell short of Eli Lilly's Tirzepatid, which achieved 25.5 percent in the same head-to-head comparison. The primary objective—demonstrating superiority over the rival—was clearly missed, a result that has dented the narrative of CagriSema as the designated successor blockbuster capable of reclaiming the GLP-1 crown.

That clinical disappointment has weighed on the stock, which slipped 2.5 percent to close at EUR 40.56. The monthly decline now stands at 9.2 percent, with a year-to-date drop of 7.9 percent. Still, some market observers caution against reading the tape too literally. The shares trade roughly 26 percent below their January peak of EUR 54.86, yet technical indicators suggest a more nuanced picture: the stock hovers near its 200-day moving average, and the Relative Strength Index sits at a neutral 48.7—hardly the profile of an oversold asset in freefall.

A Downgrade Adds to the Gloom

Adding to the cautious tone, Deutsche Bank analysts cut their rating on Thursday from Hold to Sell, trimming the price target by 9 percent to DKK 265 from DKK 275. The move reflects reduced medium-term revenue forecasts, lingering uncertainty over the impact of the US Medicare program, and concerns about the pace of growth heading into 2027. The stock responded with a modest 0.93 percent decline in Copenhagen to DKK 304.95, while the German-listed shares gave up 2.1 percent to trade at EUR 39.76—roughly 28 percent below the 52-week high.

Not everyone shares that skepticism. J.P. Morgan's Richard Wotser, for instance, actually raised his price target to DKK 275 from DKK 250, citing stronger-than-expected international sales of Ozempic and Wegovy, even as he trimmed expectations for the oral Wegovy version. The rating remains Neutral—neither a ringing endorsement nor a red flag. The broader analyst consensus leans toward caution, with a majority holding at Neutral and only a minority recommending a Buy.

China's Door Opens a Crack

Meanwhile, the regulatory landscape in Asia offers a potential bright spot. China's drug authority has accepted Novo Nordisk's application for the oral version of Wegovy, moving the company a step closer to one of the largest potential markets for obesity treatments. The filing is now under review, though no approval timeline has been set.

The development arrives as competition in the oral GLP-1 space intensifies globally. Eli Lilly has already launched its oral product, Foundayo, in the US and is pursuing regulatory approvals in more than 40 markets. In the UK, Lilly's tablet has been available by private prescription since August 24, making it the second oral GLP-1 after Novo Nordisk's Wegovy pill, which launched there in June. Germany is slated for a September 1 market entry, with Mexico expected to follow next quarter.

Despite the competitive pressure, Novo Nordisk's oral franchise retains a commanding position: the Wegovy tablet holds roughly 90 percent of weekly prescriptions among oral formulations, with approximately 1.5 million users. CEO Mike Doustar reinforced this point in a Reuters interview, asserting the company continues to control 90 percent of the oral GLP-1 market and framing the rivalry with Lilly as a non-exclusive opportunity.

The Legal and Operational Undercurrents

Beyond the clinical and regulatory headlines, a legal skirmish with Lilly continues to simmer. In late July, Novo Nordisk filed a federal lawsuit alleging misleading advertising, claiming Lilly's campaigns compared the maximum dose of Tirzepatid against lower semaglutide doses without mentioning the newly approved 7.2-mg injection of Wegovy. While the case is now over a month old, it underscores the intensity of the marketing war for physician mindshare.

Operationally, a separate development raised eyebrows: Scholar Rock reported that a fill-finish facility in Catalent Indiana—acquired by Novo Nordisk from Catalent—was removed from an approval filing for Apitegromab due to FDA citations. The issue does not directly affect Novo Nordisk's own pipeline, but it casts a spotlight on potential quality concerns at acquired production sites.

Fundamentals Tell a Steadier Story

Beneath the headline noise, the operational picture shows resilience. Second-quarter 2026 revenue came in at USD 12.1 billion, up 7 percent year over year. The company reaffirmed its full-year guidance, which projects adjusted revenue and profit growth ranging from 0 to minus 6 percent at constant exchange rates.

Management's confidence is also reflected in continued share buybacks. Between August 17 and 21, the company repurchased over one million B-shares at prices between DKK 293 and DKK 299, bringing the accumulated total under the current DKK 11.2 billion program to roughly 15 million shares.

Looking ahead, the next major catalyst arrives in the fourth quarter of 2026, when a regulatory decision on CagriSema as an obesity treatment is expected from the FDA. A missed superiority endpoint does not automatically spell approval trouble, but it does strip away the narrative of a clear market leader. Phase 3 studies for Zenagamtide and a high-dose Cagrilintide variant are also slated to run through year-end.

For now, the stock presents a genuinely two-sided picture: near-term sentiment is pressured by the Deutsche Bank downgrade and the Redefine 4 miss, while the Chinese filing and the oral franchise's dominance offer medium-term upside potential. The CagriSema decision in the fourth quarter will likely prove decisive in determining which narrative wins out.